List of Excipients in Branded Drug ARTHRITIS PAIN ACETAMINOPHEN

Generic Drugs Containing ARTHRITIS PAIN ACETAMINOPHEN

Company	Ingredient	NDC	Excipient
TARGET CORPORATION	acetaminophen	11673-673	CARNAUBA WAX
TARGET CORPORATION	acetaminophen	11673-673	CELLULOSE, MICROCRYSTALLINE
TARGET CORPORATION	acetaminophen	11673-673	HYDROXYETHYL CELLULOSE

What are the Most Frequently-Used Excipients in ARTHRITIS PAIN ACETAMINOPHEN?

# Of NDCs	Excipient
1	CARNAUBA WAX
1	CELLULOSE, MICROCRYSTALLINE
1	HYDROXYETHYL CELLULOSE

Excipient Strategy and Commercial Opportunities for Arthritis Pain Acetaminophen

Last updated: August 28, 2026

Arthritis Pain Acetaminophen is primarily a 650 mg extended-release acetaminophen product sold under branded, store-brand, and generic-style labels. The commercial opportunity is not based on active-ingredient exclusivity. It depends on dose-formulation performance, tolerability, packaging, retailer access, private-label economics, and differentiation in older consumers with chronic pain.

The strongest product strategy is an extended-release caplet with reliable 8-hour dosing, low tablet burden, clear liver-safety communication, robust moisture protection, and a cost-efficient excipient system. Acetaminophen is subject to the FDA’s OTC internal analgesic framework, so most commercial protection comes from formulation know-how, trademarks, packaging, supply contracts, and retailer positioning rather than composition-of-matter patents.

What is Arthritis Pain Acetaminophen?

Arthritis Pain Acetaminophen is an OTC oral analgesic product containing acetaminophen, generally at 650 mg per extended-release caplet.

Product attribute	Typical commercial configuration
Active ingredient	Acetaminophen
Strength	650 mg per caplet
Release profile	Extended release, commonly marketed for 8-hour dosing
Indication	Temporary relief of minor aches and pains of arthritis
Dosage form	Caplet or tablet
Primary channel	Mass retail, pharmacy, club, grocery, e-commerce
Regulatory pathway	OTC monograph or applicable OTC drug framework
Orange Book status	Generally not the relevant regulatory listing for monograph OTC products
Main competitors	Tylenol 8 HR Arthritis Pain, store-brand arthritis pain acetaminophen, immediate-release acetaminophen, NSAID products

The “arthritis pain acetaminophen” name is used across multiple products and private-label offerings. The exact inactive ingredients, manufacturing site, labeling, and legal owner therefore depend on the specific National Drug Code and labeler.

What excipients are used in Arthritis Pain Acetaminophen?

The excipient system typically combines a matrix former or coating polymer with tableting aids, disintegrants, lubricants, glidants, pigments, and film-coating materials.

Typical inactive ingredients include:

Excipient class	Common examples	Primary function
Hydrophilic matrix former	Hypromellose	Controls water penetration and drug release
Hydrophobic release modifier	Ethylcellulose, waxes	Slows dissolution and stabilizes release
Binder	Povidone, pregelatinized starch	Improves granule and tablet strength
Disintegrant	Sodium starch glycolate, crospovidone	Controls breakup of non-release portions
Filler	Microcrystalline cellulose, starch	Adds bulk and improves compression
Lubricant	Magnesium stearate, stearic acid	Reduces sticking and ejection force
Glidant	Colloidal silicon dioxide	Improves powder flow
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, colorants	Improves appearance, handling, and swallowability
Surface or polishing agent	Carnauba wax	Provides finish and handling protection

The formulation must reconcile two competing requirements. It must release acetaminophen slowly enough to support an extended dosing interval, but it must not produce excessive tablet persistence, dose dumping, or poor release under physiologically relevant conditions.

Commercial labels for extended-release acetaminophen products commonly use polymeric coatings and matrix technologies. The specific system should be verified against the applicable DailyMed label because inactive ingredients differ among branded and private-label products.[1]

How should the excipient strategy be designed?

A commercially competitive formulation should use a simple, reproducible excipient platform rather than a high-cost proprietary system unless the release profile creates a defensible market advantage.

Release-control architecture

Three formulation architectures are commercially relevant:

1. Hydrophilic matrix tablet
   Hypromellose hydrates after ingestion and forms a gel layer that controls acetaminophen diffusion. This approach is cost-efficient and familiar to contract manufacturers.

2. Hydrophobic matrix or wax-modified tablet
   Ethylcellulose, waxes, or lipid materials reduce water penetration. These systems can improve robustness but may create greater sensitivity to milling, particle size, compression force, and food conditions.

3. Coated extended-release core
   An immediate-release or partially available core is surrounded by a polymeric barrier. This can provide more control over the release curve but usually increases manufacturing complexity and coating validation requirements.

A layered or dual-release configuration can create a stronger consumer proposition by combining earlier pain relief with prolonged exposure. It also raises formulation-development, dissolution, and scale-up risk. The commercial value depends on whether the product demonstrates a meaningful performance difference from established 8-hour products.

Tablet size and swallowability

Arthritis patients are disproportionately older adults and may have dysphagia, dry mouth, reduced grip strength, or difficulty handling child-resistant packaging. The active ingredient already represents a high tablet mass. A 650 mg acetaminophen tablet therefore requires careful control of excipient loading.

Useful design options include:

• High-density direct compression to reduce tablet volume.
• Oval or capsule-shaped geometry for easier swallowing.
• Low-friction film coating.
• Debossed strength and dosing identifiers.
• Reduced coating weight where appearance permits.
• A caplet surface that minimizes tackiness under humid storage.

A smaller tablet can improve adherence but may limit release-control space. A larger tablet may accommodate a stronger matrix but reduce patient acceptance.

Excipient tolerability

The product should avoid unnecessary excipients associated with consumer restrictions or supply volatility. Potential commercial screening criteria include:

• Gluten-free status.
• Absence of artificial colors.
• Low allergen profile.
• Compatibility with vegetarian or halal product positioning.
• Minimal use of excipients with known regional labeling sensitivities.
• Availability from multiple qualified suppliers.

These attributes are not necessarily clinical differentiators, but they can affect retailer acceptance, procurement, and consumer conversion.

What formulations are protected by acetaminophen patents?

The basic acetaminophen molecule is long established and does not provide meaningful new-drug exclusivity for an OTC arthritis pain product. The commercially relevant IP categories are formulation, manufacturing process, packaging, trademarks, and trade dress.

Potentially protectable features include:

• Extended-release matrix composition.
• Polymer ratios and coating architecture.
• Multi-phase release profiles.
• Abuse-deterrent or dose-dumping-resistant designs.
• Low-friability, high-density caplet manufacture.
• Taste or swallowability improvements.
• Moisture-control packaging.
• Child-resistant unit-dose systems.
• Combination products with additional active ingredients.

Patent value depends on claim breadth, priority date, prosecution history, validity, freedom-to-operate scope, and whether the claims read on commercially practical formulations. A formulation patent that requires a narrow polymer ratio may be difficult to enforce against a generic using a different release-control mechanism.

Because this category is dominated by OTC products, patent analysis should not rely solely on the FDA Orange Book. Orange Book listing is generally associated with approved prescription and certain approved OTC products, while monograph-compliant OTC products may not have the same listing structure.[2] Product-specific patent status requires review of FDA records, USPTO records, labeler information, and litigation databases.

When does Arthritis Pain Acetaminophen lose exclusivity?

There is no single patent expiration date for the category. The active ingredient is off patent, and generic or store-brand competition is already established.

Exclusivity component	Commercial position
Acetaminophen composition of matter	Expired or not commercially relevant
OTC monograph access	Available to compliant manufacturers
650 mg extended-release formulation	May be covered by product-specific patents, but not by a universal category patent
Brand name	Protected through trademark rights
Trade dress	Potentially protected through trademark or unfair-competition law
Retail placement	Controlled by commercial contracts and buyer relationships
Manufacturing know-how	Protected through confidentiality and process controls

The loss of exclusivity for a branded product is therefore gradual rather than tied to one date. Store brands can enter when they have a compliant formulation, acceptable stability data, appropriate labeling, a qualified supplier, and retailer authorization.

What is the FDA regulatory status of Arthritis Pain Acetaminophen?

Acetaminophen is regulated as an OTC internal analgesic, antipyretic, and antirheumatic ingredient. FDA labeling requirements address indications, warnings, directions, and maximum daily use.[3]

Key regulatory issues include:

• Accurate active-ingredient declaration.
• Compliance with the applicable OTC monograph or approved application.
• Extended-release dissolution performance.
• Stability through the labeled shelf life.
• Control of acetaminophen degradation products.
• Liver-warning language.
• Maximum daily dose communication.
• Child-resistant packaging where required.
• Manufacturing under current good manufacturing practice requirements.

The FDA has emphasized the risk of severe liver injury from acetaminophen overdose, including accidental duplication across multiple products.[4] That risk has direct commercial relevance. Packaging and labeling should make the following points prominent:

• The product contains acetaminophen.
• Consumers should not combine it with other acetaminophen-containing products.
• Consumers should observe the daily maximum.
• Heavy alcohol use and liver disease require specific caution and professional guidance under applicable labeling.

A differentiated package can reduce selection errors by using large strength numerals, an explicit “8 HR” statement, and a prominent acetaminophen identification panel.

Which companies compete in Arthritis Pain Acetaminophen?

The market includes branded manufacturers, store-brand sponsors, contract manufacturers, and pharmacy distributors.

Competitor type	Typical proposition
National brand	Recognition, perceived quality, broad distribution
Retail private label	Lower price and retailer margin
Value generic	Lowest acquisition cost
Club-store pack	High count and low unit price
E-commerce brand	Search visibility, subscription, direct consumer data
Combination analgesic brand	Broader symptom positioning, with greater safety complexity

The main branded reference point is Johnson & Johnson Consumer Health’s Tylenol 8 HR Arthritis Pain. Private-label products compete on price, count size, packaging, and retailer availability. Immediate-release acetaminophen competes on lower price and rapid-release expectations, while NSAIDs compete on anti-inflammatory positioning but carry different gastrointestinal, cardiovascular, renal, and age-related risk considerations.

What commercial opportunities exist for excipient innovation?

Premium extended-release positioning

A formulation with a clinically credible and regulatorily supportable release profile can support premium pricing if it delivers:

• Consistent 8-hour performance.
• Low variability between batches.
• Strong food-effect control.
• Reduced tablet burden.
• Easy swallowing.
• Lower friability and better handling.

The burden of proof is commercial as well as technical. Consumers may not pay a premium for a release mechanism that is invisible on the label.

Senior-friendly product design

The highest-value design opportunity is often the complete delivery system rather than the tablet alone. Potential features include:

• Easy-open but compliant packaging.
• Large-print dosing instructions.
• Calendarized blister packs.
• Unit-dose systems that reduce duplicate dosing.
• High-contrast tablet markings.
• Bottles with improved grip geometry.
• Count sizes aligned with monthly or travel use.

Packaging claims must remain consistent with FDA requirements and substantiated human-factors evidence where applicable.

Private-label platform licensing

A standardized 650 mg extended-release acetaminophen platform can be licensed to multiple retailers. The platform would have greater value if it supports:

• Multiple tablet colors and imprint configurations.
• Bottle and blister formats.
• Different count sizes.
• Regional packaging requirements.
• Rapid technology transfer to qualified manufacturers.
• Consistent dissolution across sites.

The licensing model can generate revenue through formulation royalties, technical-transfer fees, quality agreements, and supply arrangements. It also creates concentration risk if one retailer accounts for a large share of volume.

Excipient and manufacturing supply opportunities

Suppliers can differentiate through:

• Direct-compression grades optimized for high drug loading.
• Controlled-release hypromellose grades.
• Low-moisture excipient systems.
• Coating systems that reduce process time.
• Continuous manufacturing compatibility.
• Dual-source supply qualification.
• Analytical methods for dissolution and degradation monitoring.

The strongest supplier proposition combines regulatory documentation, global availability, batch consistency, and process support. A low-cost excipient that increases dissolution variability or tablet defects can destroy its apparent margin advantage.

What generic launch risks exist?

Generic and private-label entry risk is high because the active ingredient is mature and widely available. The principal barriers are operational rather than fundamental patent barriers.

Risk area	Effect on launch
Extended-release dissolution failure	Delays approval or market release
Tablet size	Reduces adherence and retailer appeal
Dose dumping	Creates safety and regulatory risk
Acetaminophen degradation	Shortens shelf life or increases recalls
API supply concentration	Raises cost and continuity risk
Packaging errors	Increases duplicate-dose risk
Retailer qualification	Delays private-label launch
Product similarity	Limits pricing power
Litigation over formulation claims	Can delay or increase launch cost
Manufacturing transfer	Can alter release performance

A generic launch should be evaluated under at least three scenarios:

1. Low-price private-label launch: rapid share capture through retailer distribution, with limited formulation differentiation.
2. Premium senior-focused launch: slower adoption but stronger gross margin if packaging and adherence benefits are credible.
3. Platform licensing launch: multiple retail customers, higher scale, but greater quality-system and supply-chain complexity.

How strong is the patent estate for Arthritis Pain Acetaminophen?

The category-level patent estate is weak because acetaminophen is an old active ingredient and OTC access is broad. Product-level patent strength can still be moderate if a formulation has narrow release-control claims, strong technical data, and meaningful design-around difficulty.

Patent strength should be assessed across five dimensions:

Factor	Strong position
Claim scope	Covers multiple polymer systems or release architectures
Written description	Supports broad formulation variations
Enablement	Includes reproducible manufacturing examples
Design-around burden	Alternative formulations perform poorly or cost more
Commercial relevance	Claims cover the marketed product and process

Method-of-use patents have limited commercial value for a conventional OTC arthritis pain indication because the use is established and easily replicated. Manufacturing patents can provide more practical protection if they reduce defects, improve throughput, or solve a difficult scale-up problem.

What licensing deals are relevant?

Licensing opportunities generally fall into four structures:

• Formulation license: rights to use a controlled-release technology.
• Private-label supply agreement: manufacturer supplies finished product to a retailer.
• Co-development agreement: formulation owner and brand owner share development costs.
• Excipient technology license: polymer or coating supplier licenses a specialized platform.

No single public licensing model defines the market. Commercial diligence should focus on territory, minimum purchase obligations, quality responsibilities, change-control rights, regulatory ownership, recall allocation, and termination provisions.

What is the revenue exposure to acetaminophen competition?

Revenue exposure is highest for products dependent on national-brand pricing or a limited number of retail customers. A mature acetaminophen product can maintain volume while losing value through:

• Private-label substitution.
• Retailer price compression.
• Promotional discounts.
• Larger-count packaging.
• E-commerce price comparison.
• Switching between extended-release and immediate-release products.

A manufacturer with a low-cost, validated formulation may still obtain attractive returns because development and marketing costs are lower than for prescription medicines. Margin protection depends on manufacturing yield, tablet defects, packaging cost, channel mix, and retailer terms.

What geographic coverage applies?

The United States is governed by FDA OTC requirements and acetaminophen labeling rules. Other markets apply different nonprescription classifications, maximum strengths, warning language, and combination-product controls.

Geographic expansion requires review of:

• Local acetaminophen dose limits.
• Extended-release classification.
• Permitted excipients.
• Stability zones.
• Child-resistant packaging standards.
• Import and manufacturing requirements.
• Trademark availability.
• National product registration requirements.

A formulation designed for U.S. OTC distribution may require changes before commercialization in Canada, Europe, Asia-Pacific, or Latin America.

Key Takeaways

• Arthritis Pain Acetaminophen is generally a 650 mg extended-release acetaminophen product marketed for 8-hour arthritis pain relief.
• The active ingredient is mature; commercial protection comes from formulation, manufacturing, packaging, trademarks, and retailer relationships.
• Hypromellose, ethylcellulose, waxes, disintegrants, binders, lubricants, and film-coating materials are the main excipient tools.
• The best formulation opportunity is a low-cost, high-drug-load caplet with consistent dissolution, good swallowability, and strong moisture stability.
• FDA compliance, acetaminophen liver-safety warnings, and duplicate-dose prevention are central regulatory and commercial issues.
• Orange Book analysis is less central than OTC monograph compliance and product-specific FDA and USPTO review.
• Private-label and store-brand entry risk is high because acetaminophen is widely available and the category has limited active-ingredient exclusivity.
• Senior-friendly packaging, retailer licensing, and excipient-enabled manufacturing efficiency offer the clearest commercial opportunities.
• Manufacturing transfer, dissolution variability, supply concentration, and packaging errors are the main launch barriers.

FAQs

Can Arthritis Pain Acetaminophen use a different release mechanism from Tylenol 8 HR?

Yes. A competing product can use a different matrix, coating, or layered release system if it meets applicable FDA requirements and performs consistently. The alternative must be assessed for dissolution, stability, dose dumping, and potential patent overlap.

Is a 650 mg acetaminophen tablet automatically an extended-release product?

No. Strength alone does not establish release characteristics. The product must be labeled and manufactured as an extended-release dosage form, with supporting dissolution and stability controls.

Are natural excipients commercially advantageous in arthritis acetaminophen products?

They can support selected consumer-positioning claims, but they do not automatically improve safety, efficacy, or regulatory status. Their value depends on supply reliability, batch consistency, compatibility with the release profile, and consumer demand.

Can an acetaminophen private-label product use the same inactive ingredients as a national brand?

It may, but identical inactive ingredients do not establish freedom to operate. The manufacturer must assess formulation patents, trademarks, trade dress, regulatory requirements, and product-specific labeling.

What is the most defensible innovation for a new arthritis acetaminophen product?

A validated delivery system that combines reliable extended release, smaller or easier-to-swallow tablets, robust packaging, and reduced dosing errors is more commercially defensible than an undifferentiated excipient substitution.

References

1. U.S. National Library of Medicine. (n.d.). DailyMed: Acetaminophen extended-release tablet labels. https://dailymed.nlm.nih.gov/dailymed/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Food and Drug Administration. (n.d.). Code of Federal Regulations, Title 21, Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-343

4. U.S. Food and Drug Administration. (n.d.). Acetaminophen and liver injury: Q&A for consumers. https://www.fda.gov/drugs/information-drug-class/acetaminophen-and-liver-injury-questions-and-answers-consumers